Letrozole in symptomatic uterine fibroids

Comparing the effect of letrozole with triptorline on reducing complications in women with symptomatic uterine fibroids

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221108056446N10

Enrollment

100

Registered

2024-08-16

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic Uterine Fibroids. Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention 1: Case group: In the Case group, letrozole 5 mg tablets (From the importing company: Shafayab Gostar) are taken daily for 3 months. Intervention 2: In the control group, a 3.75 mg vial o

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women with symptomatic uterine fibroids Abnormal uterine bleeding

Exclusion criteria

Exclusion criteria: pregnancy Other uterine diseases such as malignancy Hormonal disorders Taking other drugs for the treatment of uterine fibroids The occurrence of unwanted side effects of drugs Deterioration of patients during the treatment period

Design outcomes

Primary

Measure	Time frame
Uterine fibroid size. Timepoint: Three months after taking the drug. Method of measurement: Clinical examination of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShamin Ghobadi

Esfahan University of Medical Sciences

shaminghobadi@med.mui.ac.ir+98 913 432 5676

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026